Role of SREBPs in Liver Diseases: A Mini-review.
Role of SREBPs in Liver Diseases: A Mini-review.
复制标题
DOI：
10.14218/jcth.2017.00061
复制
发表时间：
2018-09-28
影响因子：
3.6
通讯作者：
Hamidi-Zad Z
中科院分区：
文献类型：
--
作者：
Moslehi A;Hamidi-Zad Z
固醇调节元件结合蛋白(SREBPs)是一个转录因子家族，参与胆固醇、脂肪酸和甘油三酯的生物发生。它们还调节许多器官的生理功能，如甲状腺、脑、心脏、胰腺和激素合成。除生理效应外，SREBP还参与一些病理过程，如糖尿病、内质网应激、动脉粥样硬化以及与SREBP表达变化相关的慢性肾脏疾病等。在肝脏，SREBPs参与了非酒精性脂肪性肝病、非酒精性脂肪性肝炎、肝炎和肝癌的发病机制。有几种SREBP抑制剂具有治疗肥胖症、糖尿病和癌症的潜力。本文就SREBPs在器官功能生理学和肝病发病机制中的作用的最新研究成果进行综述。
Sterol regulator element binding proteins (SREBPs) are a family of transcription factors involved in the biogenesis of cholesterol, fatty acids and triglycerides. They also regulate physiological functions of many organs, such as thyroid, brain, heart, pancreas and hormone synthesis. Beside the physiological effects, SREBPs participate in some pathological processes, diabetes, endoplasmic reticulum stress, atherosclerosis and chronic kidney disease associated with SREBP expression changes. In the liver, SREBPs are involved in the pathogenesis of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatitis and hepatic cancer. There are several SREBP inhibitors that have potential for treating obesity, diabetes and cancer. This review assesses the recent findings about the roles of SREBPs in the physiology of organs’ function and pathogenesis of liver diseases.